ROXI-ASPEN

Study Details

Full Title

A PHASE 3, MULTICENTER, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE REGN7508, A FACTOR XI MONOCLONAL ANTIBODY, VERSUS ACETYLSALICYLIC ACID FOR PROPHYLAXIS OF SYMPTOMATIC VENOUS THROMBOEMBOLISM AFTER ELECTIVE TOTAL KNEE ARTHROPLASTY (ROXI-ASPEN)

Principal Investigator

Thorsten
Seyler

Protocol Number

PRO00119643

NCT ID

NCT07213778

Phase

III

Enrollment Status

Open to Enrollment